Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1520Carcinoma, Non-Small-Cell Lung 754Breast Neoplasms 572Neoplasm Metastasis 529Colorectal Neoplasms 445Melanoma 391Leukemia, Myeloid, Acute 371Multiple Myeloma 363Ovarian Neoplasms 352Recurrence 336Lymphoma 334Advanced Solid Tumors 324Lymphoma, Non-Hodgkin 314Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 232Carcinoma, Renal Cell 225Squamous Cell Carcinoma of Head and Neck 210Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 183Solid Tumors 182Carcinoma, Hepatocellular 164Hematologic Neoplasms 155Head and Neck Neoplasms 152Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

Melatonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Autism Spectrum Disorder × Clear all
NCT01903681 2014-04-04

Assessment of the Pharmacokinetics of CircadinĀ® in Children With Neurodevelopmental Disorders and Sleep Disturbances

Neurim Pharmaceuticals Ltd.

Phase 1 Completed
16 enrolled

Autism Spectrum Disorder, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔